Analysts Set Immunocore Holdings plc (NASDAQ:IMCR) Price Target at $69.18

Immunocore Holdings plc (NASDAQ:IMCR) has been given an average recommendation of “Moderate Buy” by the thirteen ratings firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, four have issued a hold rating and eight have assigned a buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $65.64.

IMCR has been the topic of a number of research analyst reports. Needham & Company LLC lowered their price target on Immunocore from $78.00 to $71.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. Mizuho downgraded shares of Immunocore from an “outperform” rating to a “neutral” rating and dropped their price target for the company from $72.00 to $38.00 in a report on Monday, November 11th. Guggenheim cut shares of Immunocore from a “buy” rating to a “neutral” rating in a report on Monday, October 7th. UBS Group assumed coverage on shares of Immunocore in a report on Thursday, October 24th. They issued a “sell” rating and a $24.00 target price on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Immunocore in a research note on Monday, September 9th.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Primecap Management Co. CA increased its stake in Immunocore by 3,841.6% in the 2nd quarter. Primecap Management Co. CA now owns 1,951,070 shares of the company’s stock worth $66,122,000 after buying an additional 1,901,570 shares in the last quarter. Armistice Capital LLC grew its position in shares of Immunocore by 495.1% during the second quarter. Armistice Capital LLC now owns 976,000 shares of the company’s stock worth $33,077,000 after purchasing an additional 812,000 shares in the last quarter. Wellington Management Group LLP grew its position in shares of Immunocore by 10.5% during the third quarter. Wellington Management Group LLP now owns 7,048,833 shares of the company’s stock worth $219,430,000 after purchasing an additional 668,382 shares in the last quarter. Millennium Management LLC raised its stake in Immunocore by 124.4% during the 2nd quarter. Millennium Management LLC now owns 600,954 shares of the company’s stock valued at $20,366,000 after purchasing an additional 333,167 shares during the period. Finally, Two Sigma Advisers LP lifted its holdings in Immunocore by 65.6% in the 3rd quarter. Two Sigma Advisers LP now owns 757,700 shares of the company’s stock worth $23,587,000 after purchasing an additional 300,200 shares in the last quarter. 84.50% of the stock is currently owned by institutional investors.

Immunocore Stock Down 4.6 %

NASDAQ:IMCR opened at $28.91 on Wednesday. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78. The firm has a market cap of $1.45 billion, a P/E ratio of -30.43 and a beta of 0.73. Immunocore has a fifty-two week low of $28.27 and a fifty-two week high of $76.98. The firm has a 50-day simple moving average of $32.28 and a two-hundred day simple moving average of $35.36.

Immunocore (NASDAQ:IMCR) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.50. The company had revenue of $80.25 million during the quarter, compared to the consensus estimate of $78.94 million. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The firm’s quarterly revenue was up 23.7% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.59) earnings per share. Analysts predict that Immunocore will post -0.94 earnings per share for the current fiscal year.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.